Valuation: Palisade Bio, Inc.

Market Cap 246M 218M 202M 184M 348M 23.32B 353M 2.43B 954M 12.17B 922M 903M 38.8B P/E 2026 *
-6.31x
P/E 2027 * -5.04x
Enterprise Value 148M 132M 122M 111M 209M 14.05B 213M 1.47B 575M 7.33B 556M 544M 23.37B EV / Sales 2026 *
338x
EV / Sales 2027 * -
Free-Float
95.73%
Yield 2026 *
-
Yield 2027 * -
1 day-8.44%
1 week-8.44%
Current month+4.44%
1 month-11.32%
3 months-28.43%
6 months-41.25%
Current year-40.00%
1 week 1.38
Extreme 1.38
1.58
1 month 1.32
Extreme 1.32
1.71
Current year 1.32
Extreme 1.32
2.86
1 year 1.32
Extreme 1.32
2.86
3 years 0.53
Extreme 0.53
22.35
5 years 0.53
Extreme 0.53
2,265
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 2022-10-09
President 48 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 67 2024-02-13
Director/Board Member 55 2018-12-31
Director/Board Member 68 2023-02-01
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Exercice

Chief Executive Officer

7,866,750 4.7423%
10/6/26 Exercice

Chairperson

6,272,802 3.7814%
10/2/26 Buy

Chairman

10,000 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
-8.44%-8.44%-18.97%-85.38% 246M
-6.60%-8.56%+49.38%+64.90% 65B
+0.03%+5.56%+9.10%+75.22% 51.2B
-4.09%-0.11%+2.22%+55.67% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-1.07%+2.33%+19.43%+20.40% 22.5B
Average -2.34%-1.16%+39.07%+83.39% 37.26B
Weighted average by Cap. -2.20%-0.50%+44.21%+103.53%

Financials

2026 *2027 *
Net sales 438K 389K 360K 328K 619K 41.52M 629K 4.33M 1.7M 21.67M 1.64M 1.61M 69.07M -
Net income -47.56M -42.27M -39.18M -35.65M -67.27M -4.51B -68.35M -471M -185M -2.36B -178M -175M -7.51B -63.69M -56.61M -52.47M -47.74M -90.09M -6.04B -91.53M -631M -247M -3.15B -239M -234M -10.06B
Net Debt -97.7M -86.85M -80.49M -73.24M -138M -9.27B -140M -968M -379M -4.84B -367M -359M -15.43B -335M -298M -276M -251M -473M -31.77B -481M -3.31B -1.3B -16.58B -1.26B -1.23B -52.84B
Projected Income Statement - Annual - Palisade Bio, Inc.
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
26-10-16 US$1.410 -8.44% 3,889,613
26-10-15 US$1.540 +4.05% 1,817,613
26-10-14 US$1.480 +1.02% 4,166,660
26-10-13 US$1.465 -7.86% 1,588,945
26-10-12 US$1.590 +3.25% 1,571,682
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Palisade Bio, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.410USD
Average target price
9.800USD
Spread / Average Target
+595.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Palisade Bio, Inc.
  1. Stock Market
  2. Stocks
  3. PALI Stock